Buscar
Phio Pharmaceuticals Corp
PHIOAñadir a la lista de seguimiento
1.050USD
0.0000.00%
Cierre 07-27 16:00（ET）Cotizaciones retrasadas 15 min
12.20MCap. mercado
PérdidaP/E TTM
Más Datos de Phio Pharmaceuticals Corp Compañía
Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company. The Company's INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. It is developing therapeutics that are designed to leverage INTASYL to target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. The Company's pipeline is focused on the treatment of cutaneous Squamous Cell Carcinoma (cSCC) and melanoma. Its product pipeline includes PH-762 and PH-894. PH-762 is an INTASYL compound designed to reduce the expression of cell death protein 1 (PD-1). PD-1 is a protein that inhibits T cells’ ability to kill cancer cells and is a clinically validated target in immunotherapy. PH-894 is an INTASYL compound that is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby affecting the immune system as well as the tumor.
Información de Phio Pharmaceuticals Corp
Símbolo de cotizaciónPHIO
Nombre de la empresaPhio Pharmaceuticals Corp
Fecha de salida a bolsaMay 10, 2012
Director ejecutivoBitterman (Robert J)
Número de empleados5
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 10
Dirección411 Swedeland Road
CiudadKING OF PRUSSIA
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal19406
Teléfono15087673861
Sitio Webhttps://phiopharma.com/
Símbolo de cotizaciónPHIO
Fecha de salida a bolsaMay 10, 2012
Director ejecutivoBitterman (Robert J)
Ejecutivos de Phio Pharmaceuticals Corp
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Robert J. Bitterman
Mr. Robert J. Bitterman
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
51.42K
+19.45%
Mr. David H. Deming
Mr. David H. Deming
Independent Director
Independent Director
37.80K
+62.96%
Dr. Curtis A. Lockshin, Ph.D.
Dr. Curtis A. Lockshin, Ph.D.
Independent Director
Independent Director
2.35K
-1307.90%
Dr. Jonathan E. Freeman, Ph.D.
Dr. Jonathan E. Freeman, Ph.D.
Independent Director
Independent Director
--
--
Ms. Patricia A. (Pat) Bradford
Ms. Patricia A. (Pat) Bradford
Independent Director
Independent Director
--
--
Ms. Lisa Carson
Ms. Lisa Carson
Principal Financial Officer, Principal Accounting Officer, Vice President - Finance and Administration
Principal Financial Officer, Principal Accounting Officer, Vice President - Finance and Administration
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Robert J. Bitterman
Mr. Robert J. Bitterman
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
51.42K
+19.45%
Mr. David H. Deming
Mr. David H. Deming
Independent Director
Independent Director
37.80K
+62.96%
Dr. Curtis A. Lockshin, Ph.D.
Dr. Curtis A. Lockshin, Ph.D.
Independent Director
Independent Director
2.35K
-1307.90%
Dr. Jonathan E. Freeman, Ph.D.
Dr. Jonathan E. Freeman, Ph.D.
Independent Director
Independent Director
--
--
Ms. Patricia A. (Pat) Bradford
Ms. Patricia A. (Pat) Bradford
Independent Director
Independent Director
--
--
Ms. Lisa Carson
Ms. Lisa Carson
Principal Financial Officer, Principal Accounting Officer, Vice President - Finance and Administration
Principal Financial Officer, Principal Accounting Officer, Vice President - Finance and Administration
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Phio Pharmaceuticals Corp?
Los cinco principales accionistas de Phio Pharmaceuticals Corp son: Mr. Robert J. Bitterman
¿Cuántas instituciones poseen acciones de Phio Pharmaceuticals Corp (PHIO)?
A fecha de 2026Q1, 41 instituciones poseen acciones de Phio Pharmaceuticals Corp, con un valor de mercado combinado de aproximadamente 1.10M, lo que representa el 9.48% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 6982.00.